Fig. 1: GBM cells that survive chemoradiotherapy treatment exhibit increased glucose uptake but decreased lactate production.

A Schematic depicting a clinically relevant in vitro chemoradiotherapy treatment model of patient-derived GBM to study temporal molecular adaptation. BT935 patient-derived GBM cells treated with TMZRT were collected at D0 (no treatment therapy-naïve control), D1, D3, D5, and D7 time-points and living cells were isolated and subjected to: B 2-NBDG glucose uptake analysis and C extracellular lactate levels measurement. N = 3 biological replicates/group, mean ± SEM analyzed using one-way ANOVA test with Dunnett’s multiple comparisons.